Skip to main content
Equibles
ARQT logo

ARQT · Arcutis Biotherapeutics, Inc. · Debt

Track ARQT — free

Use ARQT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARQT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.20 +0.31 (+0.97%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.09B
Shares
125.69M
Volume · Oct 20 4.42M Avg daily vol (3M) 2.4M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-06-30 USD 108,900,000 10-Q filed 2026-08-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 6,950,000
Noncurrent debt carrying amount
USD 101,950,000
Noncurrent operating lease liabilities 2026-06-30 USD 5,237,000 10-Q filed 2026-08-05
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 24 filings 24 filers Visit website Investor relations